| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| 2413.T - M3, Inc. | HOLD | 0 @ JPY 13.1414 | JPY 0 | The current share valuation price of 2413.T based on adjusted close was JPY 13.1414. The average price that 2413.T shares were previous bought at was JPY 14.063. The current market price is -6.6% lower than average price they were purchased at. The value of the holding in 2413.T has fallen by JPY 1,438 (USD $9) compared to the previous valuation of M3, Inc. |
| 4151.T - Kyowa Kirin Co., Ltd. | HOLD | 0 @ JPY 16.2702 | JPY 0 | The current share valuation price of 4151.T based on adjusted close was JPY 16.2702. The average price that 4151.T shares were previous bought at was JPY 15.9723. The current market price is 1.9% higher than average price they were purchased at. The value of the holding in 4151.T has increased by JPY 3,269 (USD $21) compared to the previous valuation of Kyowa Kirin Co., Ltd. however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| 4502.T - Takeda Pharmaceutical Company Limited | HOLD | 0 @ JPY 32.3062 | JPY 0 | The current share valuation price of 4502.T based on adjusted close was JPY 32.3062. The average price that 4502.T shares were previous bought at was JPY 29.4962. The current market price is 9.5% higher than average price they were purchased at. The value of the holding in 4502.T has increased by JPY 8,433 (USD $54) compared to the previous valuation of Takeda Pharmaceutical Company Limited however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| 4503.T - Astellas Pharma Inc. | HOLD | 0 @ JPY 14.1095 | JPY 0 | The current share valuation price of 4503.T based on adjusted close was JPY 14.1095. The average price that 4503.T shares were previous bought at was JPY 11.8805. The current market price is 18.8% higher than average price they were purchased at. The value of the holding in 4503.T has fallen by JPY 52,389 (USD $333) compared to the previous valuation of Astellas Pharma Inc. |
| 4507.T - Shionogi & Co., Ltd. | HOLD | 0 @ JPY 17.9722 | JPY 0 | The current share valuation price of 4507.T based on adjusted close was JPY 17.9722. The average price that 4507.T shares were previous bought at was JPY 17.3885. The current market price is 3.4% higher than average price they were purchased at. The value of the holding in 4507.T has fallen by JPY 2,554 (USD $16) compared to the previous valuation of Shionogi & Co., Ltd. |
| 4519.T - Chugai Pharmaceutical Co., Ltd. | HOLD | 0 @ JPY 52.0595 | JPY 0 | The current share valuation price of 4519.T based on adjusted close was JPY 52.0595. The average price that 4519.T shares were previous bought at was JPY 49.2596. The current market price is 5.7% higher than average price they were purchased at. The value of the holding in 4519.T has fallen by JPY 14,009 (USD $89) compared to the previous valuation of Chugai Pharmaceutical Co., Ltd. |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 28.1746 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 28.1746. The average price that 4523.T shares were previous bought at was JPY 30.2808. The current market price is -7.0% lower than average price they were purchased at. The value of the holding in 4523.T has fallen by JPY 47,403 (USD $301) compared to the previous valuation of Eisai Co., Ltd. |
| 4543.T - Terumo Corporation | HOLD | 0 @ JPY 13.6444 | JPY 0 | The current share valuation price of 4543.T based on adjusted close was JPY 13.6444. The average price that 4543.T shares were previous bought at was JPY 15.7277. The current market price is -13.2% lower than average price they were purchased at. The value of the holding in 4543.T has fallen by JPY 9,557 (USD $61) compared to the previous valuation of Terumo Corporation |
| 4568.T - Daiichi Sankyo Company, Limited | HOLD | 0 @ JPY 20.6897 | JPY 0 | The current share valuation price of 4568.T based on adjusted close was JPY 20.6897. The average price that 4568.T shares were previous bought at was JPY 26.2488. The current market price is -21.2% lower than average price they were purchased at. The value of the holding in 4568.T has fallen by JPY 67,764 (USD $430) compared to the previous valuation of Daiichi Sankyo Company, Limited |
| 4578.T - Otsuka Holdings Co., Ltd. | HOLD | 0 @ JPY 56.1405 | JPY 0 | The current share valuation price of 4578.T based on adjusted close was JPY 56.1405. The average price that 4578.T shares were previous bought at was JPY 56.2092. The current market price is -0.1% lower than average price they were purchased at. The value of the holding in 4578.T has fallen by JPY 9,575 (USD $61) compared to the previous valuation of Otsuka Holdings Co., Ltd. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 9.98735 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 9.98735. The average price that 6869.T shares were previous bought at was JPY 11.1102. The current market price is -10.1% lower than average price they were purchased at. The value of the holding in 6869.T has increased by JPY 13,605 (USD $86) compared to the previous valuation of Sysmex Corporation however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| 7733.T - Olympus Corporation | HOLD | 0 @ JPY 12.6131 | JPY 0 | The current share valuation price of 7733.T based on adjusted close was JPY 12.6131. The average price that 7733.T shares were previous bought at was JPY 12.8084. The current market price is -1.5% lower than average price they were purchased at. The value of the holding in 7733.T has fallen by JPY 9,184 (USD $58) compared to the previous valuation of Olympus Corporation |
| 7741.T - HOYA Corporation | HOLD | 0 @ JPY 159.412 | JPY 0 | The current share valuation price of 7741.T based on adjusted close was JPY 159.412. The average price that 7741.T shares were previous bought at was JPY 144.221. The current market price is 10.5% higher than average price they were purchased at. The value of the holding in 7741.T has fallen by JPY 10,399 (USD $66) compared to the previous valuation of HOYA Corporation |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 139.64 | USD 0 | The current share valuation price of A based on adjusted close was USD 139.64. The average price that A shares were previous bought at was USD 137.599. The current market price is 1.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Agilent Technologies Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 214.35 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 214.35. The average price that ABBV shares were previous bought at was USD 210.747. The current market price is 1.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of AbbVie Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 121.76 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 121.76. The average price that ABT shares were previous bought at was USD 130.554. The current market price is -6.7% lower than average price they were purchased at. USD 0 compared to the previous valuation of Abbott Laboratories however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| ALC.SW - | HOLD | 0 @ CHF 76.758 | CHF 0 | The current share valuation price of ALC.SW based on adjusted close was CHF 76.758. The average price that ALC.SW shares were previous bought at was CHF 78.6397. The current market price is -2.4% lower than average price they were purchased at. The value of the holding in ALC.SW has fallen by CHF 412,454 (USD $516,394) compared to the previous valuation of |
| ALNY - Alnylam Pharmaceuticals Inc | HOLD | 0 @ USD 359.27 | USD 0 | The current share valuation price of ALNY based on adjusted close was USD 359.27. The average price that ALNY shares were previous bought at was USD 417.546. The current market price is -14.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of Alnylam Pharmaceuticals Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| AMGN - Amgen Inc | HOLD | 0 @ USD 330.41 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 330.41. The average price that AMGN shares were previous bought at was USD 307.144. The current market price is 7.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Amgen Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| ARGX.BR - Argenx SE | HOLD | 0 @ EUR 783.838 | EUR 0 | The current share valuation price of ARGX.BR based on adjusted close was EUR 783.838. The average price that ARGX.BR shares were previous bought at was EUR 848.229. The current market price is -7.6% lower than average price they were purchased at. The value of the holding in ARGX.BR has fallen by EUR 108,218 (USD $125,803) compared to the previous valuation of Argenx SE |
| AZN.L - AstraZeneca PLC | HOLD | 0 @ GBP 186.425 | GBP 0 | The current share valuation price of AZN.L based on adjusted close was GBP 186.425. The average price that AZN.L shares were previous bought at was GBP 137.386. The current market price is 35.7% higher than average price they were purchased at. The value of the holding in AZN.L has fallen by GBP 266,886 (USD $357,742) compared to the previous valuation of AstraZeneca PLC |
| BAX - Baxter International Inc | HOLD | 0 @ USD 20.11 | USD 0 | The current share valuation price of BAX based on adjusted close was USD 20.11. The average price that BAX shares were previous bought at was USD 19.3744. The current market price is 3.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Baxter International Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| BAYN.DE - Bayer AG | HOLD | 0 @ EUR 51.6816 | EUR 0 | The current share valuation price of BAYN.DE based on adjusted close was EUR 51.6816. The average price that BAYN.DE shares were previous bought at was EUR 36.6196. The current market price is 41.1% higher than average price they were purchased at. The value of the holding in BAYN.DE has increased by EUR 82,140 (USD $95,487) compared to the previous valuation of Bayer AG however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| BDX - Becton Dickinson and Company | HOLD | 0 @ USD 207.11 | USD 0 | The current share valuation price of BDX based on adjusted close was USD 207.11. The average price that BDX shares were previous bought at was USD 189.057. The current market price is 9.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Becton Dickinson and Company however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 164.42 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 164.42. The average price that BIIB shares were previous bought at was USD 174.505. The current market price is -5.8% lower than average price they were purchased at. USD 0 compared to the previous valuation of Biogen Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 121.522 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 121.522. The average price that BIM.PA shares were previous bought at was EUR 127.104. The current market price is -4.4% lower than average price they were purchased at. The value of the holding in BIM.PA has increased by EUR 641 (USD $745) compared to the previous valuation of BioMerieux however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 55.26 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 55.26. The average price that BMY shares were previous bought at was USD 48.5469. The current market price is 13.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Bloomsbury Publishing Plc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 88.07 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 88.07. The average price that BSX shares were previous bought at was USD 98.6897. The current market price is -10.8% lower than average price they were purchased at. USD 0 compared to the previous valuation of Boston Scientific Corporation however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 88.07 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 88.07. The average price that BSX shares were previous bought at was USD 98.6897. The current market price is -10.8% lower than average price they were purchased at. USD 0 compared to the previous valuation of MULSTRXSSXIMETFP however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| CAH - Cardinal Health Inc | HOLD | 0 @ USD 212.45 | USD 0 | The current share valuation price of CAH based on adjusted close was USD 212.45. The average price that CAH shares were previous bought at was USD 181.391. The current market price is 17.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Cardinal Health Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| CI - Cigna Corp | HOLD | 0 @ USD 272.21 | USD 0 | The current share valuation price of CI based on adjusted close was USD 272.21. The average price that CI shares were previous bought at was USD 284.682. The current market price is -4.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Cigna Corp however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| CNC - Concurrent Technologies Plc | HOLD | 0 @ USD 45.75 | USD 0 | The current share valuation price of CNC based on adjusted close was USD 45.75. The average price that CNC shares were previous bought at was USD 39.8918. The current market price is 14.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of Concurrent Technologies Plc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| COH.AX - | HOLD | 0 @ AUD 180.325 | AUD 0 | The current share valuation price of COH.AX based on adjusted close was AUD 180.325. The average price that COH.AX shares were previous bought at was AUD 180.39. The current market price is 0.0% lower than average price they were purchased at. The value of the holding in COH.AX has increased by AUD 29,005 (USD $19,397) compared to the previous valuation of however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| COLO-B.CO - | HOLD | 0 @ DKK 84.5687 | DKK 0 | The current share valuation price of COLO-B.CO based on adjusted close was DKK 84.5687. The average price that COLO-B.CO shares were previous bought at was DKK 89.6653. The current market price is -5.7% lower than average price they were purchased at. The value of the holding in COLO-B.CO has fallen by DKK 296,807 (USD $46,178) compared to the previous valuation of |
| COO - The Cooper Companies, Inc. Common Stock | HOLD | 0 @ USD 82.37 | USD 0 | The current share valuation price of COO based on adjusted close was USD 82.37. The average price that COO shares were previous bought at was USD 76.7444. The current market price is 7.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of The Cooper Companies, Inc. Common Stock however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| COR - Cencora Inc. | HOLD | 0 @ USD 354.85 | USD 0 | The current share valuation price of COR based on adjusted close was USD 354.85. The average price that COR shares were previous bought at was USD 329.864. The current market price is 7.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Cencora Inc. however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| CSL.AX - | HOLD | 0 @ AUD 118.458 | AUD 0 | The current share valuation price of CSL.AX based on adjusted close was AUD 118.458. The average price that CSL.AX shares were previous bought at was AUD 119.315. The current market price is -0.7% lower than average price they were purchased at. The value of the holding in CSL.AX has increased by AUD 35,854 (USD $23,978) compared to the previous valuation of however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| CVS - CVS Health Corp | HOLD | 0 @ USD 78.6 | USD 0 | The current share valuation price of CVS based on adjusted close was USD 78.6. The average price that CVS shares were previous bought at was USD 72.6357. The current market price is 8.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of CVS Health Corp however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| DEMANT.CO - | HOLD | 0 @ DKK 34.7436 | DKK 0 | The current share valuation price of DEMANT.CO based on adjusted close was DKK 34.7436. The average price that DEMANT.CO shares were previous bought at was DKK 34.7569. The current market price is 0.0% lower than average price they were purchased at. The value of the holding in DEMANT.CO has fallen by DKK 60,202 (USD $9,366) compared to the previous valuation of |
| DGX - Quest Diagnostics Incorporated | HOLD | 0 @ USD 189.49 | USD 0 | The current share valuation price of DGX based on adjusted close was USD 189.49. The average price that DGX shares were previous bought at was USD 180.345. The current market price is 5.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Quest Diagnostics Incorporated however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 235.99 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 235.99. The average price that DHR shares were previous bought at was USD 213.532. The current market price is 10.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 235.99 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 235.99. The average price that DHR shares were previous bought at was USD 213.532. The current market price is 10.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| DIM.PA - Sartorius Stedim Biotech | HOLD | 0 @ EUR 240.133 | EUR 0 | The current share valuation price of DIM.PA based on adjusted close was EUR 240.133. The average price that DIM.PA shares were previous bought at was EUR 227.786. The current market price is 5.4% higher than average price they were purchased at. The value of the holding in DIM.PA has fallen by EUR 11,795 (USD $13,712) compared to the previous valuation of Sartorius Stedim Biotech |
| DXCM - DexCom Inc | HOLD | 0 @ USD 69.54 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 69.54. The average price that DXCM shares were previous bought at was USD 68.6003. The current market price is 1.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of DexCom Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| EL.PA - EssilorLuxottica SA | HOLD | 0 @ EUR 309.857 | EUR 0 | The current share valuation price of EL.PA based on adjusted close was EUR 309.857. The average price that EL.PA shares were previous bought at was EUR 339.841. The current market price is -8.8% lower than average price they were purchased at. The value of the holding in EL.PA has fallen by EUR 115,997 (USD $134,846) compared to the previous valuation of EssilorLuxottica SA |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 374.87 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 374.87. The average price that ELV shares were previous bought at was USD 373.653. The current market price is 0.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Elevance Health Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 374.87 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 374.87. The average price that ELV shares were previous bought at was USD 373.653. The current market price is 0.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of Elevance Health Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| ERF.PA - Eurofins Scientific SE | HOLD | 0 @ EUR 83.7149 | EUR 0 | The current share valuation price of ERF.PA based on adjusted close was EUR 83.7149. The average price that ERF.PA shares were previous bought at was EUR 58.2671. The current market price is 43.7% higher than average price they were purchased at. The value of the holding in ERF.PA has increased by EUR 457 (USD $531) compared to the previous valuation of Eurofins Scientific SE however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 84.35 | USD 0 | The current share valuation price of EW based on adjusted close was USD 84.35. The average price that EW shares were previous bought at was USD 81.4681. The current market price is 3.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Edwards Lifesciences Corp however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| FME.DE - Fresenius Medical Care AG | HOLD | 0 @ EUR 43.1844 | EUR 0 | The current share valuation price of FME.DE based on adjusted close was EUR 43.1844. The average price that FME.DE shares were previous bought at was EUR 48.972. The current market price is -11.8% lower than average price they were purchased at. The value of the holding in FME.DE has fallen by EUR 1,713 (USD $1,991) compared to the previous valuation of Fresenius Medical Care AG |
| FPH.NZ - | HOLD | 0 @ NZD 22.3726 | NZD 0 | The current share valuation price of FPH.NZ based on adjusted close was NZD 22.3726. The average price that FPH.NZ shares were previous bought at was NZD 21.4857. The current market price is 4.1% higher than average price they were purchased at. The value of the holding in FPH.NZ has fallen by NZD 1,821 (USD $1,050) compared to the previous valuation of |
| FRE.DE - Fresenius SE & Co KGaA | HOLD | 0 @ EUR 57.4667 | EUR 0 | The current share valuation price of FRE.DE based on adjusted close was EUR 57.4667. The average price that FRE.DE shares were previous bought at was EUR 54.1384. The current market price is 6.1% higher than average price they were purchased at. The value of the holding in FRE.DE has fallen by EUR 3,408 (USD $3,962) compared to the previous valuation of Fresenius SE & Co KGaA |
| GALD.SW - | HOLD | 0 @ CHF 194.216 | CHF 0 | The current share valuation price of GALD.SW based on adjusted close was CHF 194.216. The average price that GALD.SW shares were previous bought at was CHF 188.221. The current market price is 3.2% higher than average price they were purchased at. The value of the holding in GALD.SW has fallen by CHF 40,995 (USD $51,326) compared to the previous valuation of |
| GEHC - GE HealthCare Technologies Inc. | HOLD | 0 @ USD 81.75 | USD 0 | The current share valuation price of GEHC based on adjusted close was USD 81.75. The average price that GEHC shares were previous bought at was USD 80.1092. The current market price is 2.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of GE HealthCare Technologies Inc. however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 124.91 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 124.91. The average price that GILD shares were previous bought at was USD 119.195. The current market price is 4.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Guild Esports Plc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| GMAB.CO - | HOLD | 0 @ DKK 318.301 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 318.301. The average price that GMAB.CO shares were previous bought at was DKK 298.707. The current market price is 6.6% higher than average price they were purchased at. The value of the holding in GMAB.CO has fallen by DKK 309,922 (USD $48,219) compared to the previous valuation of |
| GRF.MC - Grifols SA | HOLD | 0 @ EUR 12.3326 | EUR 0 | The current share valuation price of GRF.MC based on adjusted close was EUR 12.3326. The average price that GRF.MC shares were previous bought at was EUR 12.9898. The current market price is -5.1% lower than average price they were purchased at. The value of the holding in GRF.MC has fallen by EUR 7,401 (USD $8,604) compared to the previous valuation of Grifols SA |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 24.3734 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 24.3734. The average price that GSK.L shares were previous bought at was GBP 23.5499. The current market price is 3.5% higher than average price they were purchased at. The value of the holding in GSK.L has increased by GBP 16,593 (USD $22,242) compared to the previous valuation of GlaxoSmithKline PLC however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| HCA - HCA Holdings Inc | HOLD | 0 @ USD 469.29 | USD 0 | The current share valuation price of HCA based on adjusted close was USD 469.29. The average price that HCA shares were previous bought at was USD 458.328. The current market price is 2.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of HCA Holdings Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| HIK.L - | HOLD | 0 @ GBP 20.7094 | GBP 0 | The current share valuation price of HIK.L based on adjusted close was GBP 20.7094. The average price that HIK.L shares were previous bought at was GBP 22.2665. The current market price is -7.0% lower than average price they were purchased at. The value of the holding in HIK.L has fallen by GBP 4,901 (USD $6,569) compared to the previous valuation of |
| HLN.L - Haleon PLC | HOLD | 0 @ GBP 4.8465 | GBP 0 | The current share valuation price of HLN.L based on adjusted close was GBP 4.8465. The average price that HLN.L shares were previous bought at was GBP 4.90699. The current market price is -1.2% lower than average price they were purchased at. The value of the holding in HLN.L has fallen by GBP 8,079 (USD $10,829) compared to the previous valuation of Haleon PLC |
| HOLX - Hologic Inc | HOLD | 0 @ USD 74.98 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 74.98. The average price that HOLX shares were previous bought at was USD 72.224. The current market price is 3.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Hologic Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| HUM - Hummingbird Resources PLC | HOLD | 0 @ USD 273.28 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 273.28. The average price that HUM shares were previous bought at was USD 299.463. The current market price is -8.7% lower than average price they were purchased at. USD 0 compared to the previous valuation of Hummingbird Resources PLC however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| HUM - Humana Inc | HOLD | 0 @ USD 273.28 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 273.28. The average price that HUM shares were previous bought at was USD 299.463. The current market price is -8.7% lower than average price they were purchased at. USD 0 compared to the previous valuation of Humana Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| IDXX - IDEXX Laboratories Inc | HOLD | 0 @ USD 715.37 | USD 0 | The current share valuation price of IDXX based on adjusted close was USD 715.37. The average price that IDXX shares were previous bought at was USD 648.595. The current market price is 10.3% higher than average price they were purchased at. USD 0 compared to the previous valuation of IDEXX Laboratories Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| ILMN - Illumina Inc | HOLD | 0 @ USD 141.65 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 141.65. The average price that ILMN shares were previous bought at was USD 118.55. The current market price is 19.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Illumina Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| INCY - Incyte Corporation | HOLD | 0 @ USD 106.21 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 106.21. The average price that INCY shares were previous bought at was USD 104.125. The current market price is 2.0% higher than average price they were purchased at. USD 0 compared to the previous valuation of Incyte Corporation however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| INSM - Insmed Inc | HOLD | 0 @ USD 161.42 | USD 0 | The current share valuation price of INSM based on adjusted close was USD 161.42. The average price that INSM shares were previous bought at was USD 184.91. The current market price is -12.7% lower than average price they were purchased at. USD 0 compared to the previous valuation of Insmed Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 154.463 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 154.463. The average price that IPN.PA shares were previous bought at was EUR 137.746. The current market price is 12.1% higher than average price they were purchased at. The value of the holding in IPN.PA has fallen by EUR 3,704 (USD $4,306) compared to the previous valuation of Ipsen SA |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 237.68 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 237.68. The average price that IQV shares were previous bought at was USD 208.362. The current market price is 14.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of IQVIA Holdings Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 535 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 535. The average price that ISRG shares were previous bought at was USD 543.35. The current market price is -1.5% lower than average price they were purchased at. USD 0 compared to the previous valuation of Intuitive Surgical Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 218.66 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 218.66. The average price that JNJ shares were previous bought at was USD 176.2. The current market price is 24.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Johnson & Johnson however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| LH - Laboratory Corporation of America Holdings | HOLD | 0 @ USD 270.87 | USD 0 | The current share valuation price of LH based on adjusted close was USD 270.87. The average price that LH shares were previous bought at was USD 260.653. The current market price is 3.9% higher than average price they were purchased at. USD 0 compared to the previous valuation of Laboratory Corporation of America Holdings however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| LLY - Eli Lilly and Company | HOLD | 0 @ USD 1038.4 | USD 0 | The current share valuation price of LLY based on adjusted close was USD 1038.4. The average price that LLY shares were previous bought at was USD 897.033. The current market price is 15.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Eli Lilly and Company however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| LONN.SW - | HOLD | 0 @ CHF 685.026 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 685.026. The average price that LONN.SW shares were previous bought at was CHF 674.414. The current market price is 1.6% higher than average price they were purchased at. The value of the holding in LONN.SW has fallen by CHF 19,952 (USD $24,980) compared to the previous valuation of |
| MCK - McKesson Corporation | HOLD | 0 @ USD 840.46 | USD 0 | The current share valuation price of MCK based on adjusted close was USD 840.46. The average price that MCK shares were previous bought at was USD 797.376. The current market price is 5.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of McKesson Corporation however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| MDT - Medtronic PLC | HOLD | 0 @ USD 96.76 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 96.76. The average price that MDT shares were previous bought at was USD 97.6238. The current market price is -0.9% lower than average price they were purchased at. USD 0 compared to the previous valuation of Medtronic PLC however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 108.83 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 108.83. The average price that MRK shares were previous bought at was USD 92.3416. The current market price is 17.9% higher than average price they were purchased at. USD 0 compared to the previous valuation of Marks Electrical Group PLC however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 108.83 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 108.83. The average price that MRK shares were previous bought at was USD 92.3416. The current market price is 17.9% higher than average price they were purchased at. USD 0 compared to the previous valuation of Merck & Company Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| MRK.DE - Merck KGaA | HOLD | 0 @ EUR 150.272 | EUR 0 | The current share valuation price of MRK.DE based on adjusted close was EUR 150.272. The average price that MRK.DE shares were previous bought at was EUR 136.526. The current market price is 10.1% higher than average price they were purchased at. The value of the holding in MRK.DE has fallen by EUR 1,442 (USD $1,676) compared to the previous valuation of Merck KGaA |
| MTD - Mettler-Toledo International Inc | HOLD | 0 @ USD 1460.63 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1460.63. The average price that MTD shares were previous bought at was USD 1457.06. The current market price is 0.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of Mettler-Toledo International Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| MTD - AMUNDI EUR GOV 710 | HOLD | 0 @ USD 1460.63 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1460.63. The average price that MTD shares were previous bought at was USD 1457.06. The current market price is 0.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of AMUNDI EUR GOV 710 however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 132.39 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 132.39. The average price that NBIX shares were previous bought at was USD 142.915. The current market price is -7.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Neurocrine Biosciences Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| NOVN.SW - | HOLD | 0 @ CHF 144.985 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 144.985. The average price that NOVN.SW shares were previous bought at was CHF 129.171. The current market price is 12.2% higher than average price they were purchased at. The value of the holding in NOVN.SW has increased by CHF 293,383 (USD $367,316) compared to the previous valuation of however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| NOVO-B.CO - Novo Nordisk A/S | HOLD | 0 @ DKK 58.8226 | DKK 0 | The current share valuation price of NOVO-B.CO based on adjusted close was DKK 58.8226. The average price that NOVO-B.CO shares were previous bought at was DKK 53.8823. The current market price is 9.2% higher than average price they were purchased at. The value of the holding in NOVO-B.CO has fallen by DKK 526,498 (USD $81,914) compared to the previous valuation of Novo Nordisk A/S |
| NTRA - Natera Inc | HOLD | 0 @ USD 231.25 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 231.25. The average price that NTRA shares were previous bought at was USD 193.299. The current market price is 19.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Natera Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| ORNBV.HE - Orion Oyj | HOLD | 0 @ EUR 80.4906 | EUR 0 | The current share valuation price of ORNBV.HE based on adjusted close was EUR 80.4906. The average price that ORNBV.HE shares were previous bought at was EUR 69.7395. The current market price is 15.4% higher than average price they were purchased at. The value of the holding in ORNBV.HE has fallen by EUR 7,488 (USD $8,705) compared to the previous valuation of Orion Oyj |
| PFE - Pfizer Inc | HOLD | 0 @ USD 25.65 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 25.65. The average price that PFE shares were previous bought at was USD 24.8902. The current market price is 3.1% higher than average price they were purchased at. USD 0 compared to the previous valuation of Pfizer Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| PHIA.AS - Koninklijke Philips NV | HOLD | 0 @ EUR 28.5064 | EUR 0 | The current share valuation price of PHIA.AS based on adjusted close was EUR 28.5064. The average price that PHIA.AS shares were previous bought at was EUR 26.9633. The current market price is 5.7% higher than average price they were purchased at. The value of the holding in PHIA.AS has fallen by EUR 24,247 (USD $28,187) compared to the previous valuation of Koninklijke Philips NV |
| PME.AX - | HOLD | 0 @ AUD 126.914 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 126.914. The average price that PME.AX shares were previous bought at was AUD 165.455. The current market price is -23.3% lower than average price they were purchased at. The value of the holding in PME.AX has fallen by AUD 15,444 (USD $10,328) compared to the previous valuation of |
| PODD - Insulet Corporation | HOLD | 0 @ USD 287.7 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 287.7. The average price that PODD shares were previous bought at was USD 324.308. The current market price is -11.3% lower than average price they were purchased at. USD 0 compared to the previous valuation of Insulet Corporation however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| REC.MI - Recordati Industria Chimica e Farmaceutica SpA | HOLD | 0 @ EUR 55.5227 | EUR 0 | The current share valuation price of REC.MI based on adjusted close was EUR 55.5227. The average price that REC.MI shares were previous bought at was EUR 57.8338. The current market price is -4.0% lower than average price they were purchased at. The value of the holding in REC.MI has fallen by EUR 629 (USD $731) compared to the previous valuation of Recordati Industria Chimica e Farmaceutica SpA |
| REGN - Regeneron Pharmaceuticals Inc | HOLD | 0 @ USD 733.04 | USD 0 | The current share valuation price of REGN based on adjusted close was USD 733.04. The average price that REGN shares were previous bought at was USD 722.936. The current market price is 1.4% higher than average price they were purchased at. USD 0 compared to the previous valuation of Regeneron Pharmaceuticals Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| RMD - ResMed Inc | HOLD | 0 @ USD 257.58 | USD 0 | The current share valuation price of RMD based on adjusted close was USD 257.58. The average price that RMD shares were previous bought at was USD 253.398. The current market price is 1.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of ResMed Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| RO.SW - | HOLD | 0 @ CHF 444.138 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 444.138. The average price that RO.SW shares were previous bought at was CHF 353.987. The current market price is 25.5% higher than average price they were purchased at. The value of the holding in RO.SW has increased by CHF 3,577 (USD $4,478) compared to the previous valuation of however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| ROG.SW - | HOLD | 0 @ CHF 435.104 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 435.104. The average price that ROG.SW shares were previous bought at was CHF 369.084. The current market price is 17.9% higher than average price they were purchased at. The value of the holding in ROG.SW has increased by CHF 32,130 (USD $40,227) compared to the previous valuation of however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| RPRX - Royalty Pharma Plc | HOLD | 0 @ USD 39.55 | USD 0 | The current share valuation price of RPRX based on adjusted close was USD 39.55. The average price that RPRX shares were previous bought at was USD 37.9726. The current market price is 4.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of Royalty Pharma Plc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| SAN.PA - Sanofi SA | HOLD | 0 @ EUR 91.9444 | EUR 0 | The current share valuation price of SAN.PA based on adjusted close was EUR 91.9444. The average price that SAN.PA shares were previous bought at was EUR 98.4644. The current market price is -6.6% lower than average price they were purchased at. The value of the holding in SAN.PA has fallen by EUR 109,407 (USD $127,185) compared to the previous valuation of Sanofi SA |
| SDZ.SW - | HOLD | 0 @ CHF 77.4355 | CHF 0 | The current share valuation price of SDZ.SW based on adjusted close was CHF 77.4355. The average price that SDZ.SW shares were previous bought at was CHF 63.3697. The current market price is 22.2% higher than average price they were purchased at. The value of the holding in SDZ.SW has increased by CHF 1,259 (USD $1,576) compared to the previous valuation of however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| SHL.AX - | HOLD | 0 @ AUD 15.4834 | AUD 0 | The current share valuation price of SHL.AX based on adjusted close was AUD 15.4834. The average price that SHL.AX shares were previous bought at was AUD 15.0684. The current market price is 2.8% higher than average price they were purchased at. The value of the holding in SHL.AX has fallen by AUD 1,195 (USD $799) compared to the previous valuation of |
| SHL.DE - Siemens Healthineers AG | HOLD | 0 @ EUR 51.9726 | EUR 0 | The current share valuation price of SHL.DE based on adjusted close was EUR 51.9726. The average price that SHL.DE shares were previous bought at was EUR 53.078. The current market price is -2.1% lower than average price they were purchased at. The value of the holding in SHL.DE has fallen by EUR 14,448 (USD $16,796) compared to the previous valuation of Siemens Healthineers AG |
| SIG.AX - | HOLD | 0 @ AUD 1.9262 | AUD 0 | The current share valuation price of SIG.AX based on adjusted close was AUD 1.9262. The average price that SIG.AX shares were previous bought at was AUD 1.9069. The current market price is 1.0% higher than average price they were purchased at. The value of the holding in SIG.AX has fallen by AUD 8,595 (USD $5,748) compared to the previous valuation of |
| SN.L - Smith & Nephew PLC | HOLD | 0 @ GBP 16.24 | GBP 0 | The current share valuation price of SN.L based on adjusted close was GBP 16.24. The average price that SN.L shares were previous bought at was GBP 16.9831. The current market price is -4.4% lower than average price they were purchased at. The value of the holding in SN.L has fallen by GBP 6,173 (USD $8,274) compared to the previous valuation of Smith & Nephew PLC |
| SOBI.ST - | HOLD | 0 @ SEK 35.6468 | SEK 0 | The current share valuation price of SOBI.ST based on adjusted close was SEK 35.6468. The average price that SOBI.ST shares were previous bought at was SEK 33.6845. The current market price is 5.8% higher than average price they were purchased at. The value of the holding in SOBI.ST has fallen by SEK 3,784 (USD $411) compared to the previous valuation of |
| SOLV - Solventum Corp. | HOLD | 0 @ USD 79.4799 | USD 0 | The current share valuation price of SOLV based on adjusted close was USD 79.4799. The average price that SOLV shares were previous bought at was USD 76.4973. The current market price is 3.9% higher than average price they were purchased at. USD 0 compared to the previous valuation of Solventum Corp. however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| SOON.SW - | HOLD | 0 @ CHF 266.734 | CHF 0 | The current share valuation price of SOON.SW based on adjusted close was CHF 266.734. The average price that SOON.SW shares were previous bought at was CHF 268.014. The current market price is -0.5% lower than average price they were purchased at. The value of the holding in SOON.SW has fallen by CHF 109,640 (USD $137,270) compared to the previous valuation of |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 295.074 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 295.074. The average price that SRT3.DE shares were previous bought at was EUR 268.703. The current market price is 9.8% higher than average price they were purchased at. The value of the holding in SRT3.DE has fallen by EUR 52,407 (USD $60,923) compared to the previous valuation of Sartorius AG |
| STE - STERIS plc | HOLD | 0 @ USD 268.65 | USD 0 | The current share valuation price of STE based on adjusted close was USD 268.65. The average price that STE shares were previous bought at was USD 234.676. The current market price is 14.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of STERIS plc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| STMN.SW - | HOLD | 0 @ CHF 122.05 | CHF 0 | The current share valuation price of STMN.SW based on adjusted close was CHF 122.05. The average price that STMN.SW shares were previous bought at was CHF 121.044. The current market price is 0.8% higher than average price they were purchased at. The value of the holding in STMN.SW has fallen by CHF 13,758 (USD $17,225) compared to the previous valuation of |
| SYK - Stryker Corporation | HOLD | 0 @ USD 363.78 | USD 0 | The current share valuation price of SYK based on adjusted close was USD 363.78. The average price that SYK shares were previous bought at was USD 367.019. The current market price is -0.9% lower than average price they were purchased at. USD 0 compared to the previous valuation of Stryker Corporation however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| TEVA - Teva Pharma Industries Ltd ADR | HOLD | 0 @ USD 31.76 | USD 0 | The current share valuation price of TEVA based on adjusted close was USD 31.76. The average price that TEVA shares were previous bought at was USD 23.2464. The current market price is 36.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Teva Pharma Industries Ltd ADR however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| TMO - Time Out Group plc | HOLD | 0 @ USD 618.72 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 618.72. The average price that TMO shares were previous bought at was USD 498.271. The current market price is 24.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of Time Out Group plc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 300.196 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 300.196. The average price that UCB.BR shares were previous bought at was EUR 221.359. The current market price is 35.6% higher than average price they were purchased at. The value of the holding in UCB.BR has fallen by EUR 194,486 (USD $226,089) compared to the previous valuation of UCB SA |
| UNH - UnitedHealth Group Incorporated | HOLD | 0 @ USD 331.02 | USD 0 | The current share valuation price of UNH based on adjusted close was USD 331.02. The average price that UNH shares were previous bought at was USD 411.423. The current market price is -19.5% lower than average price they were purchased at. USD 0 compared to the previous valuation of UnitedHealth Group Incorporated however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 464.93 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 464.93. The average price that UTHR shares were previous bought at was USD 459.249. The current market price is 1.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of United Therapeutics Corporation however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| VEEV - Veeva Systems Inc Class A | HOLD | 0 @ USD 222.21 | USD 0 | The current share valuation price of VEEV based on adjusted close was USD 222.21. The average price that VEEV shares were previous bought at was USD 257.913. The current market price is -13.8% lower than average price they were purchased at. USD 0 compared to the previous valuation of Veeva Systems Inc Class A however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| VRTX - Vertex Pharmaceuticals Inc | HOLD | 0 @ USD 441.36 | USD 0 | The current share valuation price of VRTX based on adjusted close was USD 441.36. The average price that VRTX shares were previous bought at was USD 436.206. The current market price is 1.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of Vertex Pharmaceuticals Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| WAT - Waters Corporation | HOLD | 0 @ USD 387.37 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 387.37. The average price that WAT shares were previous bought at was USD 359.851. The current market price is 7.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of Waters Corporation however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| WAT - MULETFWATIMETFP | HOLD | 0 @ USD 387.37 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 387.37. The average price that WAT shares were previous bought at was USD 359.851. The current market price is 7.6% higher than average price they were purchased at. USD 0 compared to the previous valuation of MULETFWATIMETFP however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| WST - West Pharmaceutical Services Inc | HOLD | 0 @ USD 259.79 | USD 0 | The current share valuation price of WST based on adjusted close was USD 259.79. The average price that WST shares were previous bought at was USD 270.005. The current market price is -3.8% lower than average price they were purchased at. USD 0 compared to the previous valuation of West Pharmaceutical Services Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| ZBH - Zimmer Biomet Holdings Inc | HOLD | 0 @ USD 87.31 | USD 0 | The current share valuation price of ZBH based on adjusted close was USD 87.31. The average price that ZBH shares were previous bought at was USD 94.5899. The current market price is -7.7% lower than average price they were purchased at. USD 0 compared to the previous valuation of Zimmer Biomet Holdings Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |
| ZTS - Zoetis Inc | HOLD | 0 @ USD 124.65 | USD 0 | The current share valuation price of ZTS based on adjusted close was USD 124.65. The average price that ZTS shares were previous bought at was USD 132.613. The current market price is -6.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of Zoetis Inc however if the holding was sold on 2026-01-19 this would crystalise an overall loss. |